Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical pharmacology of nondepolarizing neuromuscular blocking agents

From: A fresh look at paralytics in the critically ill: real promise and real concern

NMBA Peak effect (min) Recovery (min) Metabolism Renal elimination (%) Biliary elimination (%) Vagolytic effect Histamine release Critical illness polyneuromyopathy
Benzylisoquinolinium
Atracurium 2-3 30-60 Hoffman Elimination (blood) 5-10 None None + +
Cisatracurium 1-7 40-90 None None None None +
Aminosteroid
Pancuronium 2-3 80-180 Liver 40-70 10-15 +++ None +++
Rocuronium 1-2 20-60 10-30 50-75 + None +
Vecuroniurn 2-3 40-60   15-50 35-50 None None +++
  1. + minimal, ++ moderate, +++ marked.